Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2010.00, up by 68.55 points or 3.53% from its previous closing of Rs. 1941.45 on the BSE.

The scrip opened at Rs. 1964.00 and has touched a high and low of Rs. 2024.05 and Rs. 1964.00 respectively. So far 65340 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2788.00 on 24-Jul-2017 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2,024.05 and Rs. 1934.35 respectively. The current market cap of the company is Rs. 33386.77 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.05% and 28.18% respectively.

Dr Reddy’s Laboratories is expecting to launch over 15 products in the US market in 2018-19. The drug major also remained optimistic for a double digit growth in the domestic market in the ongoing financial year.

The company, which launched three products in the US during March quarter of 2017-18, has over 100 abbreviated new drug applications (ANDAs) lined up for approval with the US Food and Drug Administration (USFDA).

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.